BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 30867374)

  • 1. Novel HDAC6 selective inhibitors with 4-aminopiperidine-1- carboxamide as the core structure enhanced growth inhibitory activity of bortezomib in MCF-7 cells.
    Zhao C; Gao J; Zhang L; Su L; Luan Y
    Biosci Trends; 2019; 13(1):91-97. PubMed ID: 30867374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of novel histone deacetylase 6 inhibitors with benzyl-triazole as the core skeleton.
    Mou Z; Gao J; Miao H; Zhang L; Su L; Wang B; Luan Y
    Biosci Trends; 2019 Jul; 13(3):267-272. PubMed ID: 31155552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and evaluation of novel indirubin-based N-hydroxybenzamides, N-hydroxypropenamides and N-hydroxyheptanamides as histone deacetylase inhibitors and antitumor agents.
    Anh DT; Hai PT; Dung DTM; Dung PTP; Huong LT; Park EJ; Jun HW; Kang JS; Kwon JH; Tung TT; Han SB; Nam NH
    Bioorg Med Chem Lett; 2020 Nov; 30(22):127537. PubMed ID: 32916298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicomponent Synthesis, Binding Mode, and Structure-Activity Relationship of Selective Histone Deacetylase 6 (HDAC6) Inhibitors with Bifurcated Capping Groups.
    Reßing N; Sönnichsen M; Osko JD; Schöler A; Schliehe-Diecks J; Skerhut A; Borkhardt A; Hauer J; Kassack MU; Christianson DW; Bhatia S; Hansen FK
    J Med Chem; 2020 Sep; 63(18):10339-10351. PubMed ID: 32803970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and biological evaluation of coumarin-based N-hydroxycinnamamide derivatives as novel histone deacetylase inhibitors with anticancer activities.
    Ding J; Liu J; Zhang Z; Guo J; Cheng M; Wan Y; Wang R; Fang Y; Guan Z; Jin Y; Xie SS
    Bioorg Chem; 2020 Aug; 101():104023. PubMed ID: 32650178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of the effect of different linker chemotypes on the inhibition of histone deacetylases (HDACs).
    Linciano P; Benedetti R; Pinzi L; Russo F; Chianese U; Sorbi C; Altucci L; Rastelli G; Brasili L; Franchini S
    Bioorg Chem; 2021 Jan; 106():104462. PubMed ID: 33213894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of histone deacetylase and DNA topoisomerase II-Targeted inhibitors.
    Yamashita M; Tahara T; Hayakawa S; Matsumoto H; Wada SI; Tomioka K; Iida A
    Bioorg Med Chem; 2018 May; 26(8):1920-1928. PubMed ID: 29519604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity.
    Li S; Zhao C; Zhang G; Xu Q; Liu Q; Zhao W; James Chou C; Zhang Y
    Bioorg Chem; 2021 Nov; 116():105278. PubMed ID: 34474303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel 2, 5-diketopiperazine derivatives as potent selective histone deacetylase 6 inhibitors: Rational design, synthesis and antiproliferative activity.
    Chen X; Chen X; Steimbach RR; Wu T; Li H; Dan W; Shi P; Cao C; Li D; Miller AK; Qiu Z; Gao J; Zhu Y
    Eur J Med Chem; 2020 Feb; 187():111950. PubMed ID: 31865013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies.
    Brindisi M; Senger J; Cavella C; Grillo A; Chemi G; Gemma S; Cucinella DM; Lamponi S; Sarno F; Iside C; Nebbioso A; Novellino E; Shaik TB; Romier C; Herp D; Jung M; Butini S; Campiani G; Altucci L; Brogi S
    Eur J Med Chem; 2018 Sep; 157():127-138. PubMed ID: 30092367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A452, an HDAC6-selective inhibitor, synergistically enhances the anticancer activity of chemotherapeutic agents in colorectal cancer cells.
    Won HR; Ryu HW; Shin DH; Yeon SK; Lee DH; Kwon SH
    Mol Carcinog; 2018 Oct; 57(10):1383-1395. PubMed ID: 29917295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
    Negmeldin AT; Knoff JR; Pflum MKH
    Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined Ligand and Fragment-based Drug Design of Selective Histone Deacetylase - 6 Inhibitors.
    Ruzic D; Petkovic M; Agbaba D; Ganesan A; Nikolic K
    Mol Inform; 2019 May; 38(5):e1800083. PubMed ID: 30632697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells.
    Rosik L; Niegisch G; Fischer U; Jung M; Schulz WA; Hoffmann MJ
    Cancer Biol Ther; 2014 Jun; 15(6):742-57. PubMed ID: 24618845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of novel 1,3-diaryl-1,2,4-triazole-capped histone deacetylase 6 inhibitors with potential anti-gastric cancer activity.
    Zhang XH; Kang HQ; Tao YY; Li YH; Zhao JR; Ya-Gao ; Ma LY; Liu HM
    Eur J Med Chem; 2021 Jun; 218():113392. PubMed ID: 33831778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors.
    Itoh Y; Suzuki T; Kouketsu A; Suzuki N; Maeda S; Yoshida M; Nakagawa H; Miyata N
    J Med Chem; 2007 Nov; 50(22):5425-38. PubMed ID: 17929798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors.
    Suzuki T; Muto N; Bando M; Itoh Y; Masaki A; Ri M; Ota Y; Nakagawa H; Iida S; Shirahige K; Miyata N
    ChemMedChem; 2014 Mar; 9(3):657-64. PubMed ID: 24403121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and biological evaluation of dual mTOR/HDAC6 inhibitors in MDA-MB-231 cells.
    Yao D; Jiang J; Zhang H; Huang Y; Huang J; Wang J
    Bioorg Med Chem Lett; 2021 Sep; 47():128204. PubMed ID: 34139324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
    Cheng C; Yun F; He J; Ullah S; Yuan Q
    Eur J Med Chem; 2019 Jul; 173():185-202. PubMed ID: 31003060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors.
    Yuan Z; Sun Q; Li D; Miao S; Chen S; Song L; Gao C; Chen Y; Tan C; Jiang Y
    Eur J Med Chem; 2017 Jul; 134():281-292. PubMed ID: 28419930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.